Sep.30 -- Sen. Marsha Blackburn, a Republican from Tennessee, discusses Tuesday's presidential debate and technology and social media policy on "Bloomberg Technology."
Sep.30 -- Sen. Marsha Blackburn, a Republican from Tennessee, discusses Tuesday's presidential debate and technology and social media policy on "Bloomberg Technology."
I can easily live on a $60,000 budget (including taxes) but often it is less than that. Health insurance is probably one of the most crucial — if not the most crucial — consideration you’ll need to make before you leave your job.
How much money people have put away for retirement varies, naturally, by their age group. See how your savings stack up.
After the worst week since March, investors should be defensive, build up watchlists and await a new, positive stock market direction.
Fisker stock rose in its debut Friday on the New York Stock Exchange as blank-check mergers continue to churn out electric car stocks.
Avoid making these errors and you'll enjoy a better financial life, the money guru says.
October somewhat lived up to its name as a "jinx month" for the S&P 500. But investors who found top stocks still won big gains.
Markets are down, but not collapsing. Investors remain worried about the coronavirus, and Tuesday’s election remains up in the air. Uncertainty rules the day, exacerbated by recent market losses. Wall Street, however, expects that the bulls will start running again after next week’s results – who wins will be less important than having a result.In the meantime, market declines and low share prices make for a prime time to buy in – if you judge the bottom correctly. Do that, and the rest is just ‘buy low and sell high.’ And to that end, Wall Street’s analysts have been pointing out stocks that may have hit bottom.Using TipRanks database, we pinpointed three such stocks. Each is down significantly, but each also has a Strong Buy consensus rating and at least 30% upside potential for the coming months.Fury Gold Mines (FURY)Gold – just the precious metal asset – has grown popular during the course of 2020. The coronavirus crisis and investors’ desire for a stable store of value pushed it above $2,000 earlier this year, and one ounce of gold is still selling for over $1,800. For those who haven’t got that kind of resource, however, buying stock in gold miners may be the next best thing.Fury Gold Mines is a small-cap mining company headquartered in Toronto and focused on exploiting the vast resources of the Canadian North. With mines in British Columbia, northern Quebec, and the far-north territory of Nunavut, Fury has large gold reserves in both open pit and underground mines. World gold production dropped by 1% in the last 12 months, giving the first hint that we may be at ‘peak gold,’ and prices will soon increase further.That development would bode well for Fury, which operates at a net loss. The company formed earlier this year, as a restructure of Auryn Resources that involved a merger with Eastmain and the divestment of Peruvian mines. The result is a company that is focused on Canadian development, able to take advantage of Canada’s stable work environment.The stock saw sharp declines recently, when the new FURY ticker started trading, taking Auryn’s place in the market and keeping the older company’s trading history. The drop saw Fury shares shed 67% this month.Covering the stock for Cantor, analyst Matthew O’Keefe sees plenty of upside ahead. The analyst noted, "Based on a combined gold equivalent resource of 3.9Moz, Fury is trading $43/oz versus peers at $60/oz. We expect that, as the new management makes its mark with new drill results (towards the end of 2020 and throughout 2021) and demonstrates advancement of its projects, the stock should move up."But how much up? O’Keefe’s $2.60 price target on FURY suggests a 126% upside potential for the coming year and supports his Buy rating. (To watch O’Keefe’s track record, click here)The Wall Street analyst consensus on Fury is a Strong Buy, based on 4 Buy ratings with no Sells or Holds. The stock is selling for $1.13 and its $3.37 average price target suggests it has room to nearly double in the next 12 months. (See FURY stock analysis on TipRanks)Star Bulk Carries (SBLK)Next up, Star Bulk Carries, is a Greece-based shipping company specializing in the dry bulk ocean carry trade, the backbone of the world’s shipping industry. Star Bulk operates a fleet of 116 carriers, ranging in size from ~50,000 tons to giant Newcastlemax bulk haulers rated over 200,000 tons. The trade disruptions caused by corona were hard on the industry, and SBLK was no exception. The stock is down 47% year-to-date. However, the company’s financial performance this year has been in line with its historical pattern – the first half of a calendar year sees a net loss, while the second half sees net gains. The losses in 1H20 where normal for SBLK’s pattern – and the outlook for Q3 is a return to net profits, with EPS projected at 30 cents.Covering this stock for Deutsche Bank, analyst Amit Mehrotra notes a series of related points: “[We] think the company’s net debt position should improve by about $50M vs. 2Q levels, reflecting cash flow generation in excess of >$40M of debt paydown in 3Q. We also expect the company’s prospective breakeven to reduce to under $11k per day… While we remain frustrated by the lackluster performance of SBLK shares in the context of above-mentioned improving fundamentals...we remain very comfortable that the intrinsic value of SBLK’s equity value is improving in the current environment…” Mehrotra sums up his view of Star Bulk succinctly: “On the whole, we’re encouraged by the fundamental trajectory of the company…” The analyst rates SBLK a Buy, while his $15 price target implies an upside potential of 143% from current levels. (To watch Mehrotra’s track record, click here)With 3 recent Buy reviews, SBLK holds a unanimous Strong Buy rating from the analyst consensus. The stock is currently trading at $6.18 and has an average price target of $12.09, making the one-year upside 96%. (See SBLK stock analysis on TipRanks)Heritage-Crystal Clean (HCCI)Pollution is a problem, no matter what. We all want a clean environment to live in, and we should all care about how modern industrial pollutants are disposed of. Heritage-Crystal Clean inhabits that clean-up niche, providing environmental cleaning services, including vacuum services for street cleaning, light industrial and mechanical parts cleaning technology, and a variety of waste recovery services including recovery and disposal of oil and oil products, antifreezes, and general industrial liquid waste. It’s an important, often overlooked, and vital niche in a modern technological society.After a dip into negative territory in Q2, HCCI reported stronger results for Q3. Revenues gained sequentially from $74 million to $82 million, and EPS swung from a 31-cent loss to an 18-cent gain. Despite the positive results, both earnings and revenues remain depressed compared to the year-ago quarter, and the stock has failed to regain traction after last March’s decline. HCCI is down 49% year-to-date.Roth Capital’s Gerry Sweeney, in his comments on this stock, notes that “Revenue continues to rebound as economic activity improves from COVID shelter in place orders... The highlight in the quarter was a faster than anticipated rebound in margins. While margins are still down from last year’s pre-pandemic level of 25.7%, they are up from 2Q margins of (28.2%). The improvement was driven by higher labor utilization and leverage of assets, lower solvent costs, and the internalization of waste disposal…”Sweeney rates the stock a Buy. His $21 price target indicates confidence in a solid 32% upside for the next year. (To watch Sweeney’s track record, click here.)Over the past three months, three other analysts have thrown the hat in with a view on HCCI. The three additional Buy ratings provide the stock with a Strong Buy consensus rating. With an average price target of $20.75, investors stand to take home a 30% gain, should the target be met over the next 12 months. (See HCCI stock analysis at TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
If you’re married, you’ll often do better with a joint claiming strategy for Social Security benefits. As I wrote last time, that usually works best if the two spouses are close in age and if one spouse earned considerably more than the other did during their work lives. Divorced and widowed spouses can collect spousal or survivors’ benefits—benefits based on a spouse’s lifetime earnings—with some restrictions.
“It’s hard to argue that the country doesn’t have infrastructure problems,” says Scott Davis, CEO of Melius Research. Well, there’s a giant need for greater and more accurate coronavirus testing and tracing capabilities—and that will help the companies that supply them. (ABT)’ (ticker: ABT) six coronavirus tests drove a 39% gain in third-quarter diagnostic sales.
Nov. 3 is just the next upheaval in an extremely volatile year.
The 2020 U.S. election is taking place on Nov. 3 with President Donald Trump and former VIce President Joe Biden battling for the lead position.Gold Price Analysis: The U.S. presidential election will play a huge role in shaping the global economy and gold prices are expected to react in the run up to the election day. So how important is it for the safe haven asset gold if Biden or Trump makes it to the White House?"There is no doubt that we are likely to see increased volatility in stock markets in the run up to the election day and investors seeking traditional safe havens such as gold, particularly if the race between the two candidates gets very close and there is a growing risk of a contested outcome," writes Saida Litosh, manager of precious metals analysis at Refinitiv.Biden or Trump Impact: If the past is any indication, a second Trump administration would mean a "turbulent and polarizing first term" which in turn would add further volatility and uncertainty, although the potential for radical policies could be lower in the second term should Congress remain divided, Refinitiv highlights.However, a Biden win would represent a return to a more conventional administration resulting in less volatility associated with political risks and international tensions."Historically gold price movements in the aftermath of previous U.S. presidential elections suggests little evidence of a clear relationship between the gold price and the election outcome based on party affiliation," says Litosh.Fosterville South Exploration CEO Bryan Slusarchuk says, for thousands of years, gold has acted as a hedge against uncertainty, a currency and a store of wealth. Both Trump and Biden have promised huge amounts of stimulus and huge amounts of easing."Both [Trump and Biden] have been vocally supportive of various policies that amount to quantitative easing and therefore gold ought to react well no matter who is elected," says Slusarchuk.Stepping beyond financial conditions, which will serve to propel gold higher, we need to consider gold's function as a hedge against uncertainty, says Slusarchuk.Gold Has Explosive Upside: Slusarchuk says this election is going to be perhaps the most divisive election in the history of the United States."It may be contested, the outcome may not be certain and its legitimacy will no doubt be challenged in some circles no matter which side is victorious," says Slusarchuk.He believes a bitter, contested election would also potentially have many negative consequences and would represent the very definition of uncertainty which is something gold hedges against."I believe gold has explosive upside in the coming months and this is predicated on economic and financial conditions, but the uncertainty of the election outcome will only serve to accelerate its upward trajectory," adds Slusarchuk.Price Action: The SPDR Gold Trust (NYSE: GLD) was up 0.37% at $179 at the time of publication Monday, while the VanEck Vectors Gold Miners ETF (NYSE: GDX) was up 0.89% at $38.55.See more from Benzinga * Click here for options trades from Benzinga * Check Out The Benson On Madison Ave. With Condos On Sale From .5M (PHOTOS) * Why GameStop's Stock Is Trading Lower Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
According to Joe Biden’s tax plan, three states and New York City would see top marginal state and local tax rates of over 60 percent.
As the world increasingly demands mobility for work and learning because of the pandemic, sales of Apple's (ticker: AAPL) Macs and iPads have helped offset a decline in iPhone sales. After all, users were patiently waiting for the new 5G iPhone 12 to come out. In terms of iPhone sales, which make up the biggest single chunk of Apple's revenue, declined more than 20% year over year.
Royal Dutch Shell, Cintas, Newmont, and AbbVie were among the companies that announced dividend increases this week. Exxon Mobil maintained its payout.
The shares have a dividend yield of only 1.04%. For more attractive yields among companies with plenty of free cash flow (based on his team’s estimates) to cover current dividends and hopefully to raise them, McMahon named General Mills Inc. (GIS) with a dividend yield of 3.30%, and Diageo PLC (DEO) whose American depositary receipts have a yield of 3.21%. For some industries, different metrics are used to gauge dividend coverage, so there are three groups of stock screens below.
Visa Inc. and Mastercard Inc. are often viewed as one and the same in the investment community, but the small differences between their businesses are coming into focus as the COVID-19 alters the way people spend their money.
Nearly a year into a global pandemic the world is still on the back of its heels. In the face of ever increasing infection rates, world economies have slowed rapidly and unemployment has increased significantly, and now governments are reconsidering shutting down entire countries once again. At the same time, the federal government has failed to pass a second stimulus package to prop up individuals who have lost their jobs and may be facing homelessness, as well as the need to help state and local governments provide a backstop against their own losses.Given this backdrop, there is a lot riding on a potential vaccine and/or cure for COVID-19. There are many approaches that a lengthy list of varying companies are taking to bring their respective product to market.Any company that does successfully bring a product to market that helps in the fight against the virus may see a significant increase in revenues as well as an in-kind increase in profits. B. Riley Securities has highlighted three biotech companies that are approaching the virus from different directions. We ran the trio through TipRanks’ database to see how B. Riley's recent analysis compared to other analysts’ projections.Altimmune Inc. (ALT)Altimmune is a biopharmaceutical company that develops vaccines and immune modulating therapies. Fighting the virus is likely to need both approaches, a vaccine as well as an immune therapy. With this kind of focus, Altimmune’s fortunes changed quickly with the onset of the COVID pandemic.Altimmune produces AdCovid, a single dose, intranasal vaccine to protect against COVID-19. As B. Riley analyst Mayank Mamtani points out, Altimmune’s products “stands out in regards to lung specific IgA and CD8+ T-Cell responses” and further states that “In our view it blocks the virus at the source within the nose and respiratory tract." AdCovid’s preclinical data shows a great deal of promise.ALT stock was trading around $2 per share back in January. Once the company got involved in the fight against COVID-19, the stock jumped up to a high of $33.00 per share, but is now trading at $11; still, this is a move of +450% year-to-date. Given what Altimmune has going for it, and the potential upside, this prompted Mamtani to give Altimmune a Buy rating in his recent analysis. The analyst has a price target of $31, suggesting a potential upside of 182% from current levels. (To watch Mamtani’s track record, click here).As it turns out, there are 4 Buy ratings equating to a Strong Buy on ALT with a low price target of $31 (coming from B. Riley), an average Price target of $49 and a high price target of $80. The average Price Target equates to a potential upside move of 345%. (See ALT stock analysis on TipRanks)Arcturus Therapeutics (ARCT)Arcturus Therapeutics focuses on RNA medicines with a focus on respiratory diseases. COVID, as it may be, is a virus that attacks the respiratory system. Arcturus has a proprietary LNP delivery system that enables a safer, more deliverable method of bioavailable therapy. Regarding this method and Arcturus’ product advancements to this, B. Riley's Mayank Mamtani noted, “Along with the proprietary LNP delivery platform, rapidly biodegradable LUNAR, alongside self-transcribing and replicating mRNA (STARR) technology, implies significant safety and durability advantage."Arcturus has a strong collaboration with Duke University and the Singapore Economic Development Corp to develop LUNAR-Cov19 (ARCT-021) -- a self-replicating mRNA vaccine the might be sufficient to address the Coronavirus outbreak. The potential COVID-19 vaccine is now in a Phase 1/2 trial, and upcoming clinical results are expected in 4Q20. Given the backing and the product development, there appears to be significant potential with this product.ARCT stock started the year at $10 per share but since has jumped to today’s price of $53 this is a 430% year-to-date increase.Considering the potential for the drug making it to market, Mamtani gives ARCT a Buy rating along with an $82 price target. This equates to an upside potential of 52% from current levels.Overall, what does the street have to say about ARCT? There are a total of 6 Buy ratings and all add up to a Strong Buy consensus rating. With an average price target of $75.17, the stock is expected to rise nearly 39% over the next months. (See ARCT stock analysis on TipRanks)Heat Biologics Inc (HTBX)Heat Biologics is a biopharmaceutical that develops immunotherapies. In development is a T-Cell activation platform that is proprietary and is a strong contender in the fight against COVID-19.There are similarities to SARS-Cov-1 from 2003 and today’s COVID-19. As it turns out, and as bad as it sounds, having previously contracted the original SARS-Cov-1 in 2003 would have been a good thing. Patients that recovered from the original SARS-Cov-1 and contracted the current COVID-19, are seeing long-lasting T-Cells memory and are generally asymptomatic or have mild symptoms. Given this, Heat Biologics is using an approach to mimics the original SARS-Cov-1 to provide immunity against COVID-19.Heat Biologics is in collaboration with Waisman Biomanufacturing to manufacture COVID-19 and are preparing to deliver its products to market. As B. Riley's Mamtani points out in his recent analysis, “we view single-dose format of gp96-IgG to serve as complementary to advanced C-19 vaccine candidates in developing combination-based approaches aimed at enhancing T cell immunity."Given the potential of the immunotherapies and T-Cell activation Platform and the partnership with Waisman Biomanufacturing, this prompted Mamtani to place, once again, a Buy rating on Heat Biologics shares. The analyst suggests that if everything goes as planned, HTBX will be a $4 stock in the next 12 months, implying nearly 245% return.As for other Wall Street analysts, there is only one additional rating on HTBX, which is also bullish. The average price target among the two stands at $4.50, which suggests a potential upside of a whopping 288%. (See HTBX stock analysis on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Buying a stock is easy, but buying the right stock without a time-tested strategy is incredibly hard. So what are the best stocks to buy now or put on a watchlist?
I’ve been a stay-at-home mom for five years to a 4-year-old and 2-year-old. Obviously I need to go back to work but am I too late in the game to be able to enjoy “retirement” years? You’re definitely not too late to enjoy your future retirement years.
Alibaba and four other China internet stocks are in or near buy zones. They are somewhat shielded from U.S. and Europe coronavirus fears.